Table I.

Antibody levels and seropositivity rate for spike and nucleocapsid proteins in different participant groups

Parameters	Study participant (n)	Nucleocapsid					Spike					P value
		Number of positive	Per cent positive	Reactivity			Number of positive	Per cent positive	Reactivity
				Mean	SD	95% CI			Mean	SD	95% CI
Total	132	95	72.0	12.8	10.9	11.0-15.0	73	55.3	4.8	1.8	4.4-5.2	<0.001
Males	73	55	75.3	14.5	11.6	11.4-17.7	47	64.4	5.1	1.9	4.5-5.6	<0.001
Females	59	40	67.8	10.4	9.5	7.3-13.3	26	44.1	4.2	1.4	3.6-4.7	<0.001
Symptomatic	90	65	72.2	14.9	12.0	12.0-17.9	44	48.9	5.0	1.9	4.5-5.6	<0.001
Asymptomatic	42	30	71.4	8.1	5.9	5.9-10.3	29	69.0	4.4	1.6	3.8-5.0	0.006
ICU	28	23	82.1	18.7	13.5	12.8-24.5	17	60.7	5.8	1.6	5.0-6.6	0.02
Ward	104	72	69.2	10.9	9.2	8.7-13.1	56	53.8	4.4	1.7	4.0-5.0	<0.001
Adults
ICU	16	14	87.5	22.5	11.5	15.9-29.1	13	81.3	6.3	1.2	5.6-7.1	0.01
Ward	43	31	72.1	15.3	11.2	11.2-19.4	22	51.2	4.3	1.6	3.6-5.1	<0.001
Children
ICU	12	9	75.0	12.7	14.9	1.2-24.2	4	33.3	4.2	1.5	1.8-6.6	0.15
Ward	61	41	67.2	7.6	5.6	5.8-9.3	34	55.7	4.5	1.8	3.8-5.1	0.016

Only the samples with reactivity ≥2-fold of the naive control were considered positive for reactivity with the proteins. P values represent the significance of the difference in reactivity between spike and nucleocapsid, SD represents variation within the group and the higher and lower limits of confidence interval are at 95% CI. SD, standard deviation; ICU, intensive care unit; CI, confidence interval